Professor and Department Chair, The University of Texas MD Anderson Cancer Center
Dr. Kantarjian is professor and chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, where he is also holds the Samsung Distinguished University Chair in Cancer and associate vice president for global academic programs.
He received his medical training at the American University of Beirut and was further trained in internal medicine, oncology and hematology at the Universities of Beirut and Texas.
As a clinical-translational researcher, Dr. Kantarjian has contributed to significant improvements in the treatment of various leukemias, including the development and testing of first- and second-generation BCR-ABL inhibitors in chronic myeloid leukemia, combination therapies for acute lymphocytic leukemia, and several new treatments for acute myeloid leukemia and myelodysplastic syndrome.
Dr. Kantarjian received the Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research from the American Association for Cancer Research and the John Mendelsohn Lifetime Scientific Achievement Award from MD Anderson Cancer Center, as well as numerous other honors and awards.
He has served as principal investigator of numerous leukemia studies and has authored and co-authored more than 1,800 original articles, reviews and book chapters in journals such as the Journal of Clinical Oncology, Clinical Lymphoma, Myeloma & Leukemia, Blood, Nature Biotechnology and Haematologica.